NCT03133247View on ClinicalTrials.gov

A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

April 9, 2019

Study Completion Date

July 5, 2019

Conditions
Advanced Solid Tumors
Interventions
DRUG

SHR-1316

PD-L1

Trial Locations (1)

Unknown

Linear Clinical Research, Perth

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY

NCT03133247 - A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients | Biotech Hunter | Biotech Hunter